Literature DB >> 8346417

Evidence for the role of CR1 (CD35), in addition to CR2 (CD21), in facilitating infection of human T cells with opsonized HIV.

C C Delibrias1, M D Kazatchkine, E Fischer.   

Abstract

Complement activation by HIV results in the binding of C3 fragments to the gp160 complex and enhanced infection of C3 receptor-bearing target cells. We have studied complement-mediated enhancement of infection of the human CD4-positive T-cell line HPB-ALL which expresses the CR1 (CD35) and CR2 (CD21) receptors for C3. CR1 and CR2 are present on 15% and 40% of normal peripheral blood CD4-positive T lymphocytes respectively. Opsonization of the virus with complement resulted in a 3- to 10-fold enhancement of infection of HPB-ALL cells, as assessed by measuring the release of p24 antigen in culture supernatants throughout the culture period. Blockade of CR2 with cross-linked anti-CR2 monoclonal antibodies decreased infection to the level observed with unopsonized virus. Blocking CR1 reduced complement-mediated infection by 50-80%. Experiments using serum deficient in complement factor I demonstrated that CR1 mediates the interaction between opsonized virus and T cells in addition to its ability to serve as a cofactor for the cleavage of C3b into smaller fragments that interact with CR2. A requirement for CD4 in complement-mediated enhancement of infection was observed with HIV-1 Bru but not with HIV-1 RF. Thus, CR1 and CR2 contribute in an independent and complementary fashion to penetration of opsonized virus into complement receptor-expressing T cells. Involvement of CD4 in infection with opsonized virus depends on the viral strain.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8346417     DOI: 10.1111/j.1365-3083.1993.tb01711.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  13 in total

1.  B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1.

Authors:  J J Jakubik; M Saifuddin; D M Takefman; G T Spear
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

Review 2.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 3.  Follicular dendritic cells: dynamic antigen libraries.

Authors:  Balthasar A Heesters; Riley C Myers; Michael C Carroll
Journal:  Nat Rev Immunol       Date:  2014-06-20       Impact factor: 53.106

4.  Engineering of recombinant soluble CD46: an inhibitor of complement activation.

Authors:  D Christiansen; J Milland; B R Thorley; I F McKenzie; P L Mottram; L J Purcell; B E Loveland
Journal:  Immunology       Date:  1996-03       Impact factor: 7.397

Review 5.  Enhancing role of complement in HIV infection.

Authors:  A Mouhoub; N Thieblemont; C Delibrias; E Fischer; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

6.  Deletion of putative intronic control sequences does not alter cell or stage specific expression of Cr2.

Authors:  Kirstin M Roundy; Janis J Weis; John H Weis
Journal:  Mol Immunol       Date:  2009-09-09       Impact factor: 4.407

7.  Complement opsonization enhances friend virus infection of B cells and thereby amplifies the virus-specific CD8+ T cell response.

Authors:  Custodio Bila; Verena Oberhauser; Christoph G Ammann; Asim Ejaz; Georg Huber; Simone Schimmer; Ron Messer; Marcela Pekna; Dorothee von Laer; Ulf Dittmer; Kim J Hasenkrug; Heribert Stoiber; Zoltán Bánki
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

8.  Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.

Authors:  M Saifuddin; C J Parker; M E Peeples; M K Gorny; S Zolla-Pazner; M Ghassemi; I A Rooney; J P Atkinson; G T Spear
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

9.  Complement Protein C1q Interacts with DC-SIGN via Its Globular Domain and Thus May Interfere with HIV-1 Transmission.

Authors:  Lina Pednekar; Hrishikesh Pandit; Basudev Paudyal; Anuvinder Kaur; Maha Ahmed Al-Mozaini; Lubna Kouser; Berhane Ghebrehiwet; Daniel A Mitchell; Taruna Madan; Uday Kishore
Journal:  Front Immunol       Date:  2016-12-22       Impact factor: 7.561

10.  Efficient destruction of human immunodeficiency virus in human serum by inhibiting the protective action of complement factor H and decay accelerating factor (DAF, CD55).

Authors:  H Stoiber; C Pintér; A G Siccardi; A Clivio; M P Dierich
Journal:  J Exp Med       Date:  1996-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.